ALXO ALX Oncology Holdings

ALX Oncology Announces Upcoming Investor Conference Participation

ALX Oncology Announces Upcoming Investor Conference Participation

SOUTH SAN FRANCISCO, Calif., Sept. 01, 2022 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO) a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today announced that management will participate in two upcoming investor conferences.

Citi's 17th Annual BioPharma Conference

Format: Investor meetings

Date: Wednesday, September 7

Location: Boston, MA

H.C. Wainwright 24th Annual Global Investment Conference

Format: Fireside chat with analyst, Swayampakula Ramakanth

Date: Monday, September 12

Time: 7:00 AM Eastern Time

Location: Virtual

Webcast link: Available

A live webcast of the H.C. Wainwright fireside chat is available and can be accessed by visiting the Investors section of ALX Oncology’s website at and selecting under the News and Events tab. A replay of the webcast will be archived for up to 90 days following the fireside chat date.

About ALX Oncology

ALX Oncology is a publicly traded, clinical-stage immuno-oncology company focused on helping patients fight cancer by developing therapies that block the CD47 checkpoint pathway and bridge the innate and adaptive immune system. ALX Oncology’s lead product candidate, evorpacept, is a next generation CD47 blocking therapeutic that combines a high-affinity CD47 binding domain with an inactivated, proprietary Fc domain. Evorpacept has demonstrated promising clinical responses across a range of hematologic and solid malignancies in combination with a number of leading anti-cancer agents. ALX Oncology intends to continue clinical development of evorpacept for the treatment of multiple solid tumor indications and hematologic malignancies.

Investor Contact:

Peter Garcia

Chief Financial Officer, ALX Oncology

(650) 466-7125 Ext. 113

Argot Partners

(212) 600-1902

Media Contact:

Karen Sharma

MacDougall

(781) 235-3060



EN
01/09/2022

Underlying

ALXOALX Oncology Holdings

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ALX Oncology Holdings

 PRESS RELEASE
Free
ALXO ALX Oncology Ho...

ALX Oncology Reports First Quarter 2025 Financial Results and Provides...

ALX Oncology Reports First Quarter 2025 Financial Results and Provides Corporate Update Following announcement of prioritized development strategy for evorpacept in combination with anti-cancer antibodies at R&D Day in March, Company is on track to initiate Phase 2 ASPEN-Breast and Phase 1 ASPEN-CRC studies in mid-2025 IND clearance received from U.S. FDA for novel EGFR-targeted antibody-drug conjugate (ADC), ALX2004, paving way for mid-year clinical program initiation; Company to host webcast focused on ALX2004 research program on May 20Company will not pursue U.S. registrational path in ...

May 8, 2025 1 EN
 PRESS RELEASE
Free
ALXO ALX Oncology Ho...

ALX Oncology to Report First Quarter 2025 Financial Results on May 8, ...

ALX Oncology to Report First Quarter 2025 Financial Results on May 8, 2025 SOUTH SAN FRANCISCO, Calif., May 02, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or the “Company”) (Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients’ lives, today announced plans to report its first quarter 2025 financial results on Thursday, May 8th, 2025, before market open. The company will not be hosting a teleconference in conjunction with its financial results press release. About ALX OncologyA...

May 2, 2025 1 EN
 PRESS RELEASE
Free
ALXO ALX Oncology Ho...

ALX Oncology Announces Encouraging Final Results from Phase 1 Trial Ev...

ALX Oncology Announces Encouraging Final Results from Phase 1 Trial Evaluating Evorpacept in Combination with Standard-of-Care Treatment in Patients with B-cell Non-Hodgkin Lymphoma - Data to be presented at AACR 2025 Annual Meeting suggest the combination of ALX Oncology’s investigational CD47-blocker, evorpacept, plus rituximab and lenalidomide (R2) was well-tolerated and demonstrated promising anti-tumor activity - Combination generated complete responses (CR) in 83% of patients with indolent relapsed or refractory B-cell non-Hodgkin lymphoma (B-NHL) comparing favorably to 34% historica...

April 25, 2025 1 EN
 PRESS RELEASE
Free
ALXO ALX Oncology Ho...

ALX Oncology Reports ASPEN-03 and ASPEN-04 Phase 2 Trials Evaluating E...

ALX Oncology Reports ASPEN-03 and ASPEN-04 Phase 2 Trials Evaluating Evorpacept with a Checkpoint Inhibitor for the Treatment of Head and Neck Cancers Did Not Meet Primary Endpoints In ASPEN-03 and ASPEN-04 trials, efficacy data do not support advancing evorpacept in combination with Merck’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), into a registrational studyCompany remains confident in continuing to pursue evorpacept in multiple clinical trials, based on the different mechanism of evorpacept in combination with anti-cancer antibodies, as evidenced by durable clinical response and cons...

April 25, 2025 1 EN
 PRESS RELEASE
Free
ALXO ALX Oncology Ho...

ALX Oncology Receives IND Clearance from U.S. FDA for ALX2004, a Nove...

ALX Oncology Receives IND Clearance from U.S. FDA for ALX2004, a Novel EGFR-targeted Antibody-drug Conjugate ALX2004 is a potential best- and first-in-class antibody-drug conjugate (ADC) for the treatment of EGFR-expressing solid tumors that was created from ALX Oncology’s proprietary linker-payload platformALX2004, the company’s first ADC, was fully designed and developed in-house by ALX Oncology scientistsCompany expects to initiate Phase 1 clinical trials of ALX2004 in mid-2025, with initial safety data available in 1H 2026 SOUTH SAN FRANCISCO, Calif., April 07, 2025 (GLOBE NEWSWIRE)...

April 7, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch